Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

Cited In for PubMed (Select 21343577)

1.

Type 1 diabetes and osteoporosis: from molecular pathways to bone phenotype.

Khan TS, Fraser LA.

J Osteoporos. 2015;2015:174186. doi: 10.1155/2015/174186. Epub 2015 Mar 22. Review.

2.

Use of oral bisphosphonates in primary prevention of fractures in postmenopausal women: a population-based cohort study.

Real J, Galindo G, Galván L, Lafarga MA, Rodrigo MD, Ortega M.

PLoS One. 2015 Apr 10;10(4):e0118178. doi: 10.1371/journal.pone.0118178. eCollection 2015.

3.

Current perspectives on bisphosphonate treatment in Paget's disease of bone.

Wat WZ.

Ther Clin Risk Manag. 2014 Nov 20;10:977-83. doi: 10.2147/TCRM.S58367. eCollection 2014. Review.

4.

Bisphosphonate drug holidays: Can we recommend currently?

Tandon VR, Sharma S, Mahajan A.

J Midlife Health. 2014 Jul;5(3):111-4. doi: 10.4103/0976-7800.141186. Review.

5.

Questioning the association between bisphosphonates and atypical femoral fractures.

Pazianas M, Kim SM, Yuen T, Sun L, Epstein S, Zaidi M.

Ann N Y Acad Sci. 2015 Jan;1335:1-9. doi: 10.1111/nyas.12551. Epub 2014 Oct 7. Review.

PMID:
25294742
6.

Long term bisphosphonate therapy & atypical femoral fractures: a word of caution.

Reddy SV.

Indian J Med Res. 2014 Jul;140(1):8-10. No abstract available.

7.

Bilateral atypical femoral fractures in a patient with multiple myeloma treated with intravenous bisphosphonate therapy.

Tonogai I, Goto T, Hamada D, Iwame T, Yoshioka S, Tsutsui T, Goda Y, Egawa H, Sairyo K.

Case Rep Orthop. 2014;2014:452418. doi: 10.1155/2014/452418. Epub 2014 Jul 22.

8.

Atypical femoral fracture combined with osteonecrosis of jaw during osteoporosis treatment with bisphosphonate.

Won Y, Lim JR, Kim YH, Song HK, Yang KH.

J Bone Metab. 2014 May;21(2):155-9. doi: 10.11005/jbm.2014.21.2.155. Epub 2014 May 31.

9.

Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy.

Kostoff MD, Saseen JJ, Borgelt LM.

Int J Womens Health. 2014 Apr 28;6:423-8. doi: 10.2147/IJWH.S57549. eCollection 2014.

10.

Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.

Wang Z, Ward MM, Chan L, Bhattacharyya T.

Osteoporos Int. 2014 Aug;25(8):2109-16. doi: 10.1007/s00198-014-2738-x. Epub 2014 May 21.

11.

Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.

Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, Goltzman D, Hanley DA, Hodsman A, Josse R, Jovaisas A, Juby A, Kaiser S, Karaplis A, Kendler D, Khan A, Ngui D, Olszynski W, Ste-Marie LG, Adachi J.

Can Fam Physician. 2014 Apr;60(4):324-33. Review.

12.

The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate.

Bajaj D, Geissler JR, Allen MR, Burr DB, Fritton JC.

Bone. 2014 Jul;64:57-64. doi: 10.1016/j.bone.2014.03.045. Epub 2014 Apr 1.

PMID:
24704262
13.

Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures.

Fukuda F, Kurinomaru N, Hijioka A.

Biol Ther. 2014 Jan 29. [Epub ahead of print]

14.

A network modeling approach for the spatial distribution and structure of bone mineral content.

Li H, Zhang A, Bone L, Buyea C, Ramanathan M.

AAPS J. 2014 May;16(3):478-87. doi: 10.1208/s12248-014-9585-8. Epub 2014 Mar 27.

15.

Using fractional polynomials to model the effect of cumulative duration of exposure on outcomes: applications to cohort and nested case-control designs.

Austin PC, Park-Wyllie LY, Juurlink DN.

Pharmacoepidemiol Drug Saf. 2014 Aug;23(8):819-29. doi: 10.1002/pds.3607. Epub 2014 Mar 24.

16.

Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption.

Stuible M, Moraitis A, Fortin A, Saragosa S, Kalbakji A, Filion M, Tremblay GB.

J Biol Chem. 2014 Mar 7;289(10):6498-512. doi: 10.1074/jbc.M113.494542. Epub 2014 Jan 20.

17.

Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?

Xu XL, Gou WL, Wang AY, Wang Y, Guo QY, Lu Q, Lu SB, Peng J.

J Transl Med. 2013 Dec 11;11:303. doi: 10.1186/1479-5876-11-303. Review.

18.

Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: sensitivity and trim and fill studies.

Liu J, Zhang HX, Lu XX, Hu JJ, Deng LF.

Genet Test Mol Biomarkers. 2014 Feb;18(2):117-22. doi: 10.1089/gtmb.2013.0331. Epub 2013 Nov 8. Review.

19.

Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions.

Ruza I, Mirfakhraee S, Orwoll E, Gruntmanis U.

Ther Adv Musculoskelet Dis. 2013 Aug;5(4):182-98. doi: 10.1177/1759720X13485829.

20.

Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture.

Rossini M, Lello S, Sblendorio I, Viapiana O, Fracassi E, Adami S, Gatti D.

Drug Des Devel Ther. 2013 Jul 22;7:601-10. doi: 10.2147/DDDT.S47807. Print 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk